Groupama Asset Managment Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Groupama Asset Managment reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,172 shares of the biopharmaceutical company’s stock after selling 5,871 shares during the quarter. Groupama Asset Managment’s holdings in Gilead Sciences were worth $4,984,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the fourth quarter worth approximately $29,000. Crews Bank & Trust purchased a new stake in Gilead Sciences during the fourth quarter worth $31,000. Finally, Stephens Consulting LLC boosted its position in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Piper Sandler boosted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Oppenheimer raised their price target on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 4th. Bank of America boosted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Finally, JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $105.12.

Gilead Sciences Trading Down 0.7 %

Shares of NASDAQ:GILD opened at $111.28 on Wednesday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The business has a 50 day moving average of $106.25 and a two-hundred day moving average of $95.40. The company has a market capitalization of $138.58 billion, a PE ratio of 300.76, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 302,785 shares of company stock worth $30,503,250 in the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.